US health watchdog rejects Sanofi's MS drug

December 30, 2013

French drug giant Sanofi announced Monday US health authorities had rejected its Lemtrada drug for some forms of multiple sclerosis, which is already approved in the European Union, Canada and Australia.

The Food and Drug Administration (FDA) said Sanofi's subsidiary Genzyme, which makes the drug aimed at treating relapsing forms of the disease, had "not submitted evidence from adequate and well-controlled studies that demonstrate the benefits of Lemtrada outweigh its serious adverse effects."

The FDA has also decided "one or more" clinical trials are necessary before approval of the drug—a move Sanofi said would likely prevent the drug from being approved on the US market by March 31 next year, as originally planned.

"We are extremely disappointed with the outcome of the review and the implications for patients in the US suffering with who remain in need of alternative therapies to manage a devastating disease," Genzyme President David Meeker said in a statement.

"Genzyme strongly disagrees with the FDA's conclusions and plans to appeal the agency's decision," the statement added.

Lemtrada is one of the most promising drugs in Sanofi's pipeline, and was a key motivation behind the French firm's 2011 takeover of Genzyme for more than $20 billion.

The drug is already approved in the European Union, Canada and Australia.

Multiple sclerosis, a degenerative disease of the nervous system which disrupts the brain's ability to communicate with the body, affects some 2.1 million people in the world, including 410,000 in the United States.

According to Sanofi, the most common side effects of Lemtrada include infections of the and urinary tract and lymphopenia—a reduction in the number of lymphocytes, a subset of . Serious autoimmune conditions can also occur.

Explore further: Genzyme board rejects Sanofi bid

Related Stories

Genzyme board rejects Sanofi bid

August 30, 2010

The board of directors at US biotechnology firm Genzyme has unanimously rejected an 18.5-billion-dollar takeover offer from French pharmaceutical giant Sanofi-Aventis, Genzyme said Monday.

Sanofi-Aventis says gets US approval for Genzyme bid

October 20, 2010

French pharmaceutical giant Sanofi-Aventis said on Wednesday that US competition authorities had not raised any objections to its hostile bid for US biotechnology group and rare disease specialist Genzyme.

Sanofi extends bid for Genzyme

December 13, 2010

French pharmaceutical giant Sanofi-Aventis said Monday it had extended its bid for US biotechnology group Genzyme without improving an offer that attracted only a fraction of Genzyme shares.

Sanofi-Aventis to buy Genzyme for $20.1 bln cash

February 16, 2011

(AP) -- French drug maker Sanofi-Aventis SA has agreed to buy Genzyme Corp. in a sweetened all-cash $20.1 billion deal that ends months of corporate haggling and positions Sanofi at the forefront of the market in lucrative ...

Aubagio approved for multiple sclerosis

September 13, 2012

(HealthDay)—Aubagio (teriflunomide) has been approved by the U.S. Food and Drug Administration to treat adults with relapsing forms of multiple sclerosis (MS).

US approves new multiple sclerosis capsules

March 27, 2013

The U.S. Food and Drug Administration said Wednesday it approved a new drug from Biogen Idec to control multiple sclerosis in adults with hard-to-treat forms of the disease.

Recommended for you

Non-addictive painkiller shows promise in animal trials

August 30, 2016

(HealthDay)—Preliminary research in monkeys suggests that a new medication might be able to provide pain relief similar to opioid drugs such as OxyContin, but without the same potential for addiction or serious side effects.

Mylan launching cheaper, generic version of EpiPen

August 29, 2016

The maker of EpiPens will start selling a cheaper, generic version of the emergency allergy shots as the furor over repeated U.S. price hikes continues—and looming competition threatens its near-monopoly.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.